A method to test for the possibility of antibody-mediated rejection in animals undergoing ABO-incompatible kidney transplantation.

By using CD31 proteins modified with ABO blood group antigens to detect anti-A and anti-B antibodies in body fluids, the method enhances the accuracy of predicting antibody-related rejection in kidney transplants, ensuring safer transplantation outcomes.

JP7594755B2Active Publication Date: 2024-12-05NIIGATA UNIVERSITY +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021106564
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-06-28
Publication Date
2024-12-05
Estimated Expiration
2041-06-28

AI Technical Summary

Technical Problem

Conventional methods for measuring antibody titers in ABO blood group incompatible kidney transplants fail to accurately predict antibody-related rejection, leading to unpredictable outcomes where kidneys may need to be removed despite low antibody titers or high titers not indicating rejection.

Method used

A method involving contacting body fluid samples from test animals with CD31 proteins modified with ABO blood group antigens to detect anti-A and anti-B antibodies, using immunoassays to determine binding levels, and comparing them to predetermined reference values to assess the risk of antibody-related rejection.

Benefits of technology

This method provides a more accurate prediction of antibody-related rejection, allowing for safer kidney transplantation by identifying high-risk individuals before the procedure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594755000005
    Figure 0007594755000005
  • Figure 0007594755000006
    Figure 0007594755000006
  • Figure 0007594755000007
    Figure 0007594755000007
Patent Text Reader

Abstract

To provide a method for testing the possibility of an antibody-associated rejection in a test animal performing an ABO blood group incompatible renal transplantation more precisely than a conventional method.SOLUTION: Disclosed is method for testing the possibility of antibody-associated rejection in a test animal performing an ABO blood group incompatible renal transplantation. This method includes: a contact step of bringing a body fluid sample derived from a test animal into contact with three kinds of glycoproteins consisting of CD 31 to which an antigen of any one of ABO blood group antigens is added; and a detection step of detecting the anti-A antibody and anti-B antibody bound to each of CD 31 to which CD31 and B antibody having the A antibody added among glycoproteins included in the body fluid sample.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for testing the possibility of antibody-mediated rejection in an animal undergoing an ABO blood type incompatible kidney transplant. [Background technology]

[0002] Since the first successful ABO blood type incompatible kidney transplant in Japan in 1989, various efforts have been made to improve the outcome. Currently, ABO blood type incompatible kidney transplants have a high success rate and enable long-term graft survival, accounting for 25% of living donor kidney transplants and making a significant contribution to the treatment of chronic renal failure. However, there are still a small number of cases in which the transplanted kidney must be removed early after transplantation due to uncontrollable antibody-mediated rejection, and there is an urgent need to solve this problem.

[0003] In ABO-incompatible kidney transplants, antibody titration against donor blood group antigens is the only method to predict antibody-mediated rejection. Conventionally, antibody titration using red blood cells has been used.

[0004] Meanwhile, the inventors have reported in basic research using a mass spectrometer that blood group antigens on red blood cells and renal vascular endothelial cells are structurally different (see, for example, Non-Patent Document 1, etc.). [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Tasaki M et al., “Identification and characterization of major proteins carrying ABO blood group antigens in the human kidney.”, Transplantation, Vol. 87, Issue 8, pp. 1125-1133, 2009. Summary of the Invention [Problem to be solved by the invention]

[0006] There are some cases where there is no correlation between the antibody titer measured using red blood cells, which is the conventional method, and the clinical course. In other words, while there are cases where the progress is good despite high antibody titers, there are also cases where the transplanted kidney must be removed due to severe antibody-mediated rejection even if the antibody titer increase is only slight. Therefore, a method is needed to more accurately measure the antibody titer in body fluid samples from test animals against donor blood group antigens in ABO blood type incompatible kidney transplants and to predict the possibility of antibody-mediated rejection.

[0007] The present invention has been made in view of the above circumstances, and provides a method for testing the possibility of antibody-mediated rejection in an animal undergoing ABO blood type incompatible kidney transplantation, which is more accurate than conventional methods. [Means for solving the problem]

[0008] That is, the present invention includes the following aspects. (1) A method for testing the possibility of antibody-mediated rejection in an animal undergoing ABO blood type incompatible kidney transplantation, comprising the steps of: a contacting step of contacting a body fluid sample derived from the subject animal with three types of glycoproteins consisting of CD31 protein to which any one of ABO blood group antigens has been attached; a detection step of detecting anti-A antibodies and anti-B antibodies bound to the CD31 protein bound to the A antigen and the CD31 protein bound to the B antigen, respectively, among the glycoproteins contained in the body fluid sample; Including, In the detection step, the method tests the possibility of antibody-mediated rejection in the subject animal by comparing with a predetermined standard that if the binding amount of the anti-A antibody or the anti-B antibody to the CD31 protein attached to the A antigen or the CD31 protein attached to the B antigen exceeds a predetermined standard value, there is a high possibility of antibody-mediated rejection occurring, and if the binding amount is equal to or less than the predetermined standard value, there is a low possibility of antibody-mediated rejection occurring. (2) The method according to (1), wherein the body fluid sample is blood, serum, or plasma. Effect of the Invention

[0009] According to the method of the above embodiment, it is possible to test the possibility of antibody-mediated rejection in a subject animal undergoing ABO blood type incompatible kidney transplantation more accurately than conventional methods. [Brief description of the drawings]

[0010] [Figure 1A] FIG. 1 shows a protocol for preparing recombinant CD31 having ABO blood group sugar chain antigens added thereto in an example. [Figure 1B] FIG. 1 shows a method for analyzing anti-A antibody and anti-B antibody levels using a CD31-ABO microarray in an example. [Diagram 2] 1 is a graph showing the results of a receiver operating characteristic (ROC) curve analysis for predicting antibody-mediated rejection (ABMR) based on early anti-A antibody and anti-B antibody levels measured by CD31-ABO microarray in Example 1. A is a graph of anti-A antibody, and B is a graph of anti-B antibody. [Diagram 3] 1 is a graph showing a comparison of anti-A IgG antibody and anti-B IgG antibody between isohemagglutinin method and CD31-ABO microarray method in volunteers and hemodialysis patients in Example 1. a is a graph of anti-A IgG antibody in volunteers, b is a graph of anti-A IgG antibody in hemodialysis patients, c is a graph of anti-B IgG antibody in volunteers, and d is a graph of anti-B IgG antibody in hemodialysis patients. The x-axis is the isohemagglutinin titer in log2 scale, and a titer of 0 is displayed as 1 on the graph. The y-axis is the antibody level of CD31-ABO microarray. [Figure 4]1 is a graph showing a comparison of anti-A IgM and anti-B IgM antibodies between isohemagglutinin method and CD31-ABO microarray method in volunteers and hemodialysis patients in Example 1. a is a graph of anti-A IgM antibodies in volunteers, b is a graph of anti-A IgM antibodies in hemodialysis patients, c is a graph of anti-B IgM antibodies in volunteers, and d is a graph of anti-B IgM antibodies in hemodialysis patients. The x-axis is isohemagglutinin titer in log2 scale, and titer 0 is displayed as 1 on the graph. The y-axis is antibody level of CD31-ABO microarray. [Diagram 5] 1 is a graph showing a comparison of anti-A IgG and anti-A IgM antibodies between the isohemagglutinin method and the CD31-ABO microarray method in A blood type incompatible kidney transplant patients in Example 1. All samples were collected before desensitization therapy for ABO blood type incompatible kidney transplants. a is a graph of anti-A IgG antibodies, and b is a graph of anti-A IgM antibodies. Circles are the results of patients whose IgG and IgM antibody levels are both greater than 30,000 on the CD31-ABO microarray. Squares are the results of patients whose IgG or IgM antibody levels are greater than 30,000 on the CD31-ABO microarray. △ is the results of patients whose IgG and IgM antibody levels are both less than 30,000 on the CD31-ABO microarray. The x-axis is the isohemagglutinin titer in log2 scale, and a titer of 0 is displayed as 1 on the graph. The y-axis is the antibody level of the CD31-ABO microarray. [Figure 6]1 is a graph showing a comparison of anti-B IgG and anti-B IgM antibodies between isohemagglutinin method and CD31-ABO microarray method in type B incompatible kidney transplant patients in Example 1. All samples were collected before desensitization therapy for ABO blood type incompatible kidney transplants. a is a graph of anti-B IgG antibodies, and b is a graph of anti-B IgM antibodies. Circles are the results of patients whose IgG and IgM antibody levels are both over 30,000 on the CD31-ABO microarray. Squares are the results of patients whose IgG or IgM antibody levels are over 30,000 on the CD31-ABO microarray. △ is the results of patients whose IgG and IgM antibody levels are both less than 30,000 on the CD31-ABO microarray. The x-axis is the isohemagglutinin titer in log2 scale, and a titer of 0 is displayed as 1 on the graph. The y-axis is the antibody level of the CD31-ABO microarray. [Figure 7] 1 is a graph showing a comparison of anti-A IgG and anti-A IgM antibodies between the isohemagglutinin method and the CD31-ABO microarray method in A blood type incompatible kidney transplant patients in Example 1. All samples were collected after ABO blood type incompatible kidney transplantation. a is a graph of anti-A IgG antibodies, and b is a graph of anti-A IgM antibodies. Circles are the results of patients whose IgG and IgM antibody levels are both greater than 30,000 on the CD31-ABO microarray. Squares are the results of patients whose IgG or IgM antibody levels are greater than 30,000 on the CD31-ABO microarray. △ is the results of patients whose IgG and IgM antibody levels are both less than 30,000 on the CD31-ABO microarray. The x-axis is the isohemagglutinin titer in log2 scale, and a titer of 0 is displayed as 1 on the graph. The y-axis is the antibody level of the CD31-ABO microarray. [Figure 8]A graph showing the comparison of anti-B IgG and anti-B IgM antibodies between the isohemagglutinin method and the CD31-ABO microarray method in B-type incompatible kidney transplant patients in Example 1. All samples were collected after ABO blood type-incompatible kidney transplantation. a is the graph of anti-B IgG antibody, and b is the graph of anti-B IgM antibody. The circles are the results of patients with both IgG antibody level and IgM antibody level exceeding 30,000 in the CD31-ABO microarray. The squares are the results of patients with either IgG antibody level or IgM antibody level exceeding 30,000 in the CD31-ABO microarray. The triangles are the results of patients with both IgG antibody level and IgM antibody level less than 30,000 in the CD31-ABO microarray. The x-axis is the isohemagglutinin titer on a log2 scale, and a titer of 0 is displayed as 1 on the graph. The y-axis is the antibody level of the CD31-ABO microarray.

Mode for Carrying Out the Invention

[0011] <Method for Testing the Possibility of Antibody-Related Rejection in Test Animals Undergoing ABO Blood Type-Incompatible Kidney Transplantation> The method for testing the possibility of antibody-related rejection in test animals undergoing ABO blood type-incompatible kidney transplantation in this embodiment (hereinafter simply referred to as "the method of this embodiment") includes the following steps. A contact step of contacting a body fluid sample derived from the test animal with three types of glycoproteins composed of CD31 protein to which any one of the ABO blood type antigens is added; A detection step of detecting anti-A antibodies and anti-B antibodies each bound to the CD31 protein to which the A antigen is added and the CD31 protein to which the B antigen is added among the glycoproteins contained in the body fluid sample.

[0012] In the detection step, the possibility of antibody-mediated rejection in the subject animal is tested by comparing with a criterion that if the binding amount of the anti-A antibody or the anti-B antibody to the CD31 protein attached with the A antigen or the CD31 protein attached with the B antigen exceeds a predetermined standard value, there is a high possibility of antibody-mediated rejection occurring, and if the binding amount is equal to or less than a predetermined standard value, there is a low possibility of antibody-mediated rejection occurring.

[0013] The inventors have previously demonstrated that PECAM1 (CD31) is the main protein carrying ABO blood group antigens on renal vascular endothelial cells, and is different from Band 3 and the like on red blood cells. Focusing on this structural feature, the inventors have developed a new antibody titer measurement method using a glycoprotein in which ABO blood group antigens are attached to CD31, and have found that it is possible to analyze immune responses to blood group antigens specific to renal vascular endothelial cells, not blood cells, and have thus completed the present invention.

[0014] According to the method of the present embodiment, the onset of antibody-mediated reactions after ABO-incompatible kidney transplantation can be accurately predicted before ABO-incompatible kidney transplantation, and ABO-incompatible kidney transplantation can be performed more safely. That is, the timing for performing the method of the present embodiment is preferably before the subject animal undergoes ABO-incompatible kidney transplantation.

[0015] Next, each step constituting the method of this embodiment will be described in detail below.

[0016] <Contact process> In the contacting step, a body fluid sample derived from a test animal is contacted with three types of glycoproteins consisting of CD31 protein to which any one of ABO blood group antigens has been attached.

[0017] The body fluid sample derived from a subject animal is not particularly limited as long as it is collected from the living body of the subject, and examples thereof include, but are not limited to, blood, serum, plasma, urine, buffy coat, saliva, semen, thoracic exudate, cerebrospinal fluid, tears, sputum, mucus, lymph, ascites, pleural fluid, amniotic fluid, bladder washing, bronchoalveolar lavage fluid, hair, stool, cells or tissues collected directly from the living body, etc. Among these, blood, serum, or plasma is preferred.

[0018] In this specification, the term "subject animal" refers to an animal to be subjected to a test, i.e., an animal providing a test sample. The subject animal may be either a patient with a kidney-related disease or a healthy individual. Among them, a person suspected of having a kidney-related disease, a person who has suffered from a kidney-related disease, or a patient with a kidney-related disease is preferable, and a patient with a kidney-related disease is more preferable. The patient with a kidney-related disease is not particularly limited, but a patient who requires a kidney transplant due to end-stage renal failure is preferable.

[0019] Furthermore, as the test animal, humans are preferred since the distribution and existence pattern of ABO blood types are likely to differ depending on the animal.

[0020] The above three types of glycoproteins are, namely, CD31 protein with A type antigen attached, CD31 protein with B type antigen attached, and CD31 protein with H(O) type antigen attached.

[0021] The CD31 protein to which each of the above-mentioned antigens is added can be prepared, for example, by using the method shown in the Examples below. Specifically, cells expressing each sugar chain are prepared by overexpressing only α-1,2-fucosyltransferase (FUT1), α-1,2-fucosyltransferase (FUT1) and α-1,3-N-acetylgalactosaminyltransferase (GT-A), or α-1,2-fucosyltransferase (FUT1) and α-1,3-galactosyltransferase (GT-B) in kidney-derived cells such as HEK293 cells. Next, an expression vector containing the sugar chain binding region of PECAM1 (CD31) is transfected into the cells expressing each of the prepared sugar chains, and the CD31 protein to which each of the antigens is added is produced from the cells in the culture medium. The produced CD31 protein to which each of the antigens is added can be isolated by purifying it using a known protein purification method.

[0022] Each of the CD31 proteins to which an antigen is attached is preferably immobilized on a solid support.

[0023] Examples of materials for the solid phase carrier include polymeric compounds such as polystyrenes, polyethylenes, polypropylenes, polyesters, poly(meth)acrylonitriles, styrene-butadiene copolymers, poly(meth)acrylic esters, fluororesins, cross-linked dextran, and polysaccharides; glass; metals; magnetic materials; resin compositions containing magnetic materials; and combinations of these.

[0024] The shape of the solid phase carrier is not particularly limited, and examples include tray-like, spherical, particulate, fibrous, rod-like, disc-like, container-like, cell, microplate, microfluidic device, test tube, and the like. Among these, in the method of this embodiment, a microplate is preferred because the presence or absence of anti-A antibody or anti-B antibody against the CD31 protein to which each antigen is added can be detected at once in the detection step described below.

[0025] The method of binding the CD31 protein to which each antigen has been added to a solid-phase carrier includes a physical adsorption method, a covalent bond method, an ionic bond method, and other chemical binding methods. Examples of the physical adsorption method include a method of directly immobilizing the CD31 protein to which each antigen has been added to a solid-phase carrier, and a method of chemically binding the CD31 protein to other proteins such as albumin and then adsorbing and immobilizing the CD31 protein. Examples of the chemical binding method include a method of directly binding the CD31 protein to the solid-phase carrier using a functional group that is introduced onto the surface of the solid-phase carrier and is capable of reacting with the CD31 protein to which each antigen has been added, a method of chemically introducing a spacer molecule (such as an epoxy-based silane coupling agent) between the solid-phase carrier and the CD31 protein to which each antigen has been added, and a method of binding the CD31 protein to which each antigen has been added to other proteins such as albumin and then chemically binding the protein to the solid-phase carrier.

[0026] Furthermore, when the solid phase carrier is a microplate, examples of a method for producing a microplate on which CD31 protein having each antigen attached thereto is immobilized include the method described in WO 2009 / 057755 (Reference 1).

[0027] The contact step may be carried out using salts, proteins such as albumin, surfactants, and the like, in addition to the above-mentioned components, if necessary.

[0028] The temperature in the contact step is usually within the range of 2° C. or more and 42° C. or less, and the contact time is usually 5 minutes or more and 24 hours or less.

[0029] In the contact step, the pH in the system is not particularly limited, but is preferably in the range of pH 5 to 10, more preferably pH 6 to 8. In order to maintain the desired pH, a buffer solution is usually used, such as a phosphate buffer solution, a tris(hydroxymethyl)aminomethane buffer solution, a HEPES buffer solution, or an MES buffer solution.

[0030] <Detection process> In the detection step, anti-A antibodies and anti-B antibodies bound to the CD31 protein to which the A antigen has been attached and to the CD31 protein to which the B antigen has been attached, among the glycoproteins contained in the body fluid sample, respectively, are detected.

[0031] The detection method in the detection step may be an immunoassay, such as enzyme immunoassay (EIA), ELISA, chemiluminescent enzyme immunoassay (CLEIA), fluorescent immunoassay (FIA), radioimmunoassay (RIA), luminescent immunoassay, immunoblot, Western blot, etc. Among them, the CLEIA method or ELISA method is preferred because it can detect antibodies easily and sensitively. Examples of the ELISA method include an indirect method, a competitive method, and a sandwich method.

[0032] For example, an example of the method of this embodiment when using the CLEIA method or the ELISA method is shown. First, the CD31 protein to which each antigen is added is bound and fixed to a solid phase carrier, and then a body fluid sample from a test animal is contacted to form a complex consisting of each glycoprotein and an antibody bound to the glycoprotein. A secondary antibody bound to a labeling substance is added thereto to form a further complex. Then, by detecting the amount of label in the formed complex, the amount of anti-A antibody and anti-B antibody present in the body fluid sample can be indirectly measured by detecting the signal generated from the labeling substance.

[0033] Examples of labeling substances include alkaline phosphatase (ALP), fluorescent substances, and charged molecules such as mellitic acid. Examples of fluorescent substances include known quantum dots, indocyanine green (ICG), Cy3, Cy5, Cy5.5, Cy7, Cy7.5, AlexaFluor, rhodamine, GFP, FITC (Fluorescein), and TAMRA. When the labeling substance is ALP, the bound anti-A antibody and anti-B antibody can be detected by adding an ALP luminescent substrate. Examples of ALP luminescent substrates include p-nitrophenyl phosphate (PNP), 4-methylumbelliferyl phosphate (4MUP), 3-(2'-spiroadamantane)4-methoxy-4-(3''-phosphoryloxy)phenyl-1,2-dioxetane (AMPPD), and Disodium 3-(4-methoxyspiro{1,2-dioxetane-3,2'-(5'-chloro)tricyclo[3.3.1.1 3,7 ]decan}-4-yl)phenyl phosphate (CSPD), 2-chloro-5-(4-methoxyspiro{1,2-dioxetane-3,2'-(5'-chloro)-tricyclo[3.3.1.1 3,7 ]decane}-4-yl)-1-phenylphosphate disodium (CDP-Star), etc.

[0034] In the detection process, the possibility of antibody-mediated rejection in the subject animal is evaluated by comparing with a criterion that if the binding amount of anti-A antibody or anti-B antibody to CD31 protein attached with A antigen or CD31 protein attached with B antigen exceeds a predetermined standard value, there is a high possibility of antibody-mediated rejection occurring, and if the binding amount is equal to or less than a predetermined standard value, there is a low possibility of antibody-mediated rejection occurring.

[0035] Specifically, when the amount of binding of anti-A antibody or anti-B antibody in a body fluid sample to CD31 protein attached with A antigen or CD31 protein attached with B antigen exceeds a predetermined standard value, the test animal from which the body fluid sample was collected is evaluated as having a high possibility of developing an antibody-mediated rejection reaction. On the other hand, when the amount of binding of anti-A antibody and anti-B antibody in a body fluid sample to CD31 protein attached with A antigen and CD31 protein attached with B antigen are both equal to or less than a predetermined standard value, the test animal from which the body fluid sample was collected is evaluated as having a low possibility of developing an antibody-mediated rejection reaction.

[0036] More specifically, for example, when the blood type of a kidney donor is type A and the blood type of a recipient is type B or type O, and the possibility of an antibody-mediated reaction after an ABO blood type incompatible kidney transplant in the recipient is evaluated, if the binding amount of anti-A antibodies in a body fluid sample derived from the recipient to the CD31 protein attached with the A antigen exceeds a predetermined reference value, the recipient is evaluated as having a high possibility of antibody-mediated rejection. On the other hand, if the binding amount of anti-A antibodies in a body fluid sample derived from the recipient to the CD31 protein attached with the A antigen is equal to or less than a predetermined reference value, the recipient is evaluated as having a low possibility of antibody-mediated rejection.

[0037] For example, when the blood type of a kidney donor is B and the blood type of a recipient is A or O, and the possibility of an antibody-mediated reaction after an ABO blood type incompatible kidney transplant in the recipient is evaluated, if the binding amount of anti-B antibody in a body fluid sample derived from the recipient to the CD31 protein attached with the B antigen exceeds a predetermined reference value, the recipient is evaluated as having a high possibility of antibody-mediated rejection. On the other hand, if the binding amount of anti-B antibody in a body fluid sample derived from the recipient to the CD31 protein attached with the B antigen is equal to or less than a predetermined reference value, the recipient is evaluated as having a low possibility of antibody-mediated rejection.

[0038] For example, when the blood type of a kidney donor is AB and the blood type of a recipient is A, B, or O, and the possibility of an antibody-mediated reaction after an ABO blood type incompatible kidney transplant in a recipient is evaluated, if at least one of the binding amount of anti-A antibody in a body fluid sample derived from the recipient to the CD31 protein added with the A antigen and the binding amount of anti-B antibody in a body fluid sample derived from the recipient to the CD31 protein added with the B antigen exceeds a predetermined standard value, the recipient is evaluated as having a high possibility of antibody-mediated rejection. On the other hand, if both the binding amount of anti-A antibody in a body fluid sample derived from the recipient to the CD31 protein added with the A antigen and the binding amount of anti-B antibody in a body fluid sample derived from the recipient to the CD31 protein added with the B antigen are equal to or less than a predetermined standard value, the recipient is evaluated as having a low possibility of antibody-mediated rejection.

[0039] Alternatively, by evaluating in advance, for example, at the time of donor selection, whether the binding amount of anti-A antibodies in a body fluid sample derived from the recipient to the CD31 protein attached with the A antigen and the binding amount of anti-B antibodies in a body fluid sample derived from the recipient to the CD31 protein attached with the B antigen are above or below a predetermined standard value, a kidney from a donor with a blood type suitable for the recipient can be selected for transplantation.

[0040] The above-mentioned reference value is a reference value for distinguishing between a group that develops antibody-mediated rejection and a group that does not develop antibody-mediated rejection.

[0041] The above-mentioned reference value can be experimentally determined as a threshold value capable of distinguishing between a patient group who developed an antibody-mediated reaction after ABO blood type incompatible kidney transplantation and a patient group who did not develop an antibody-mediated reaction after ABO blood type incompatible kidney transplantation by measuring the amount of anti-A antibody and anti-B antibody present in a body fluid sample. The method for determining the reference value for the amount of anti-A antibody and anti-B antibody present in a body fluid sample in the method of this embodiment is not particularly limited, and can be determined, for example, using a general statistical method.

[0042] Specifically, the method for determining the reference value involves, for example, measuring the amount of anti-A antibody and anti-B antibody present in a body fluid sample collected in advance before ABO blood type incompatible kidney transplantation (e.g., at the time of hospitalization, etc.) for a patient who has developed an antibody-mediated reaction after ABO blood type incompatible kidney transplantation. After measuring multiple patients, the amount of anti-A antibody and anti-B antibody present in these body fluid samples is calculated from the average or median, etc., and a numerical value including this amount can be used as the reference value.

[0043] In addition, for patients who developed antibody-mediated reactions after multiple ABO blood type incompatible kidney transplants and patients who did not develop antibody-mediated reactions after multiple ABO blood type incompatible kidney transplants, the amounts of anti-A antibodies and anti-B antibodies present in body fluid samples collected in advance before ABO blood type incompatible kidney transplants (e.g., at the time of hospitalization, etc.) are measured, and the amounts and variance of anti-A antibodies and anti-B antibodies present in body fluid samples of the patient group who developed antibody-mediated reactions after multiple ABO blood type incompatible kidney transplants and the patient group who did not develop antibody-mediated reactions after ABO blood type incompatible kidney transplants are calculated from the average value, median value, etc., and a threshold value that distinguishes between the two values ​​while taking the variance into consideration is determined, and this can be used as the reference value.

[0044] In addition to the blood sample from the subject animal in which anti-A and anti-B antibodies are to be detected, a control sample may be prepared. Examples of the control sample include a negative control sample that does not contain anti-A and anti-B antibodies, and a positive control sample that contains anti-A and anti-B antibodies. In this case, by comparing the results obtained from the negative control sample that does not contain anti-A and anti-B antibodies with the results obtained from the positive control sample that contains anti-A and anti-B antibodies, it is possible to more accurately detect the amounts of anti-A and anti-B antibodies present in the body fluid sample from the subject animal. It is also possible to prepare a series of control samples in which the amounts of anti-A antibodies and anti-B antibodies present are changed in stages, obtain the detection results for each control sample as numerical values, create a standard curve, and quantitatively detect the amounts of anti-A antibodies and anti-B antibodies present in the body fluid sample derived from the test animal based on the standard curve and the numerical values ​​of the body fluid sample derived from the test animal.

[0045] Specifically, as a preferred embodiment, for example, when the subject animal is a human and the detection of the binding amount of anti-A antibody and anti-B antibody to the CD31 protein bound to the A antigen and the CD31 protein bound to the B antigen is performed by measuring the fluorescence intensity using a standard substance and a fluorescently labeled (preferably Cy3-labeled) anti-human IgG or IgM antibody as a secondary antibody, if the binding amount of anti-A antibody and anti-B antibody represented by the standardized fluorescence intensity by dividing by the fluorescence intensity of the standard substance exceeds a predetermined standard value, it is evaluated that there is a high possibility of antibody-mediated rejection reaction occurring. On the other hand, if the binding amount is equal to or less than the predetermined standard value, it is evaluated that there is a low possibility of antibody-mediated rejection reaction occurring.

[0046] <Other processes> The method of this embodiment may further include other steps in addition to the contacting step and the detecting step.

[0047] For example, a washing step may be provided after the contact step and before the detection step. In the washing step, the complexes formed in the contact step, each of which is composed of a glycoprotein and an antibody bound to the glycoprotein, are washed. This removes contaminants such as unreacted components. The system containing the complexes in the contact step may be washed as is.

[0048] The washing step is usually carried out by different methods depending on the shape of the solid phase carrier to which the glycoprotein is bound. When the solid phase carrier is particulate, for example, the solid phase carrier is washed by dispersing it in a washing solution, or by immersing it in the magnetically collected state. On the other hand, when the solid phase carrier is in the form of a microplate, the solid phase carrier is washed by contacting the surface with a washing solution.

[0049] The washing solution is preferably a washing solution containing a surfactant and the buffer solution mentioned in the contact step. The pH of the washing solution is preferably in the range of pH 5 to 10, more preferably pH 6 to 8. Specifically, the washing solution may be a Tris-buffered saline solution (pH 7.5) containing 25 mM Tris-HCl, 140 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 mM MnCl2, and 1 v / v% Triton X-100.

[0050] In the above detection step, after contacting a complex consisting of each glycoprotein and an antibody bound to the glycoprotein with a secondary antibody, a washing solution can be added to wash the complex bound to the secondary antibody, thereby removing unreacted substances and impurities in the sample, and allowing the complex to be detected with higher sensitivity by the secondary antibody. EXAMPLES

[0051] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.

[0052] [Materials and measurement methods] (Sample and Data Collection) A total of 252 plasma samples were collected. Volunteers (n = 120) donated blood samples to the Japanese Red Cross Blood Center. Approval for this study was obtained from the review committee of the Japanese Red Cross Society (approval number 28J0001). Samples were donated without personal identifiers. The only demographic factor available was the ABO blood type of these samples. Other plasma samples were collected from patients (n = 80) undergoing hemodialysis and patients (n = 52) undergoing ABO blood type incompatible kidney transplantation (hereafter sometimes referred to as "ABOi KTx") at Niigata University Medical and Dental Hospital, Nagoya Second Red Cross Hospital, and Hokkaido University Hospital. All transplants were kidney transplants from living donors. Clinical and laboratory information was extracted from electronic databases and patients' medical records. Transplant patients were divided into two groups; patients without acute antibody-mediated rejection (ABMR) (ABMR(-)), and patients with acute ABMR due to anti-A or anti-B antibodies after ABO blood type incompatible kidney transplantation (ABMR(+)). Patients without acute ABMR never experienced acute ABMR due to anti-A or anti-B antibodies after ABO blood type incompatible kidney transplantation. The study was approved by the hospital's institutional ethics committee (approval number 2018-0311) and was conducted in accordance with the guidelines of the Declaration of Helsinki. Informed consent was obtained individually from all participants included in the study.

[0053] [Anti-ABO antibody isohemagglutinin titer] Anti-A and anti-B antibody titrations were performed using conventional test tube methods. Specifically, the transplant patient's plasma was serially diluted with saline, and 3 v / v% (50 μL) of the RBC suspension was mixed with the transplant patient's plasma (100 μL) in a test tube. After stirring using a vortex mixer, the suspension was left to stand at room temperature for 15 minutes, and the IgM antibody titer was determined by visually checking the agglutination reaction. To measure the titer of IgG antibodies, an equal volume of 0.01 M dithiothreitol (DTT, Wako Pure Chemical Industries, Ltd.) diluted with 7.4 v / v% phosphate-buffered saline (PBS) was reacted with the transplant patient's plasma at 37°C for 30 to 60 minutes to inactivate the IgM antibodies. After washing three times with saline, the RBC suspension was incubated with DTT-treated transplant patient's plasma. After washing again three times with physiological saline, anti-human IgG antibodies (Bio-Rad Anti-human IgG, Bio-Rad Laboratories, for USA volunteers; Ortho Anti-human IgG, Ortho Diagnostics, for Japanese transplant patients) were added to determine the IgG antibody titers. Immediately before determining each antibody titer, the mixtures were centrifuged at 900 × g or more and 1,000 × g or less for 15 seconds using a Himac centrifuge MC-450.

[0054] [Immunosuppression in ABO-incompatible kidney transplantation] Immunosuppressive therapy was performed according to each institution's protocol. Plasma exchange or double filtration plasma exchange was performed before ABO-incompatible kidney transplantation to reduce antibody titers. Before 2003, splenectomy was performed on the day of ABO-incompatible kidney transplantation, and since 2004, rituximab was used instead of splenectomy. Calcineurin inhibitors, methylprednisolone, mycophenolate mofetil, and basiliximab were administered for induction therapy, except in a few cases.

[0055] [ABMR diagnosis] Episode biopsies were performed if rejection was clinically suspected. Two or three core biopsy samples were obtained using a spring-loaded 16-gauge biopsy gun under ultrasound guidance. Rejection was diagnosed by a pathologist at each institution using the Banff classification. Anti-A or anti-B ABMR was diagnosed using pathological findings when anti-donor human leukocyte antigen (HLA) antibodies were not detected.

[0056] [Preparation of recombinant CD31 carrying ABO blood group carbohydrate antigens] FIG. 1A shows a protocol for preparing recombinant CD31 tagged with ABO blood group carbohydrate antigens. Recombinant CD31 protein (rCD31) tagged with ABO blood group carbohydrate antigens was produced using glycoengineered human embryonic kidney cells (HEK293 cells). H-type carbohydrate-expressing cells were established by overexpression of the α-1,2-fucosyltransferase (FUT1) gene in HEK293 cells. The resulting cells were named HEK293H. A- and B-glycan expressing cells were established by overexpressing α-1,3-N-acetylgalactosaminyltransferase (GT-A) and α-1,3-galactosyltransferase (GT-B), respectively, in HEK293H cells, and the resulting cells were named HEK293A and HEK293B.

[0057] The cDNA encoding the extracellular domain of CD31 was amplified by polymerase chain reaction (PCR) using the following primers: cDNA derived from human umbilical vein endothelial cells was used as a template. Forward primer: 5'-aagcttcaggATGCAGCCGAGGTGGGCCCA-3' (SEQ ID NO: 1, including a HindIII site) Reverse primer: 5'-gcggccgcTTCTTCCATGGGGCAAGAATGA-3' (SEQ ID NO: 2, including NotI site)

[0058] A DNA fragment of approximately 1.8 kb was amplified and subcloned into the pCRII-blunt vector (Life Technologies). After confirming the correct sequence using a Genetic Analyzer 3130×1 (Applied Biosystems), the fragment excised with HindIII and NotI was inserted into the pcDNA3.1N-F expression vector modified from pcDNA3.1N(+) (Life Technologies) by introducing a sequence encoding DYKDDDDK (SEQ ID NO: 3) and a stop codon. The resulting plasmid (pcDNA3.1N-CD31-F) was transfected into HEK293H, HEK293A, and HEK293B cells in culture medium using Lipofectamine LTX (Life Technologies) according to the protocol to generate rCD31 with a C-terminus FLAG tag. After culturing at 37°C for 48 to 72 hours, each medium was collected and rCD31 was purified using anti-FLAG M2 agarose affinity gel (Sigma-Aldrich). Briefly, 300 mL of medium was mixed with 500 μL of anti-FLAG M2 agarose affinity gel suspension and stirred slowly at 4°C for several hours. After centrifugation, the gel was washed 2 to 5 times with PBS containing 0.01 v / v% Tween-20, and rCD31 was eluted from the affinity gel using FLAG peptide (Sigma-Aldrich). The protein concentration of the purified rCD31 was determined using a NanoDrop LITE spectrophotometer (Thermo Scientific) and named H-CD31, A-CD31, and B-CD31, respectively.

[0059] [Preparation of CD31 protein from human kidney] Renal tissues were collected with informed consent from patients who underwent nephrectomy due to renal cancer at Niigata University Medical and Dental Hospital. Proteins were extracted from normal renal cortex of patients with different ABO blood types, and CD31 protein was purified. Briefly, protein extracts were incubated with Dynabeads Protein G (VERITAS) pre-bound to anti-CD31 antibody (Santa Cruz Biotechnology). Dynabeads were washed extensively with lysis solution and eluted with sodium dodecyl sulfate (SDS) sample buffer. The eluate with sodium dodecyl sulfate (SDS) sample buffer was separated by SDS-polyacrylamide gel electrophoresis (PAGE). The SDS-PAGE gel piece containing CD31 protein with a molecular weight of approximately 130 kDa was excised for mass spectrometry (MS).

[0060] [MS analysis of CD31 glycopeptides] Identification of N-glycosylated Asn sites and site-specific analysis of the glycan composition and structure of both rCD31 and CD31 proteins from human kidney were performed using IGOT and Glyco-RIDGE, respectively. Briefly, CD31 protein was S-carbamoylmethylated and sequentially digested with lysyl endopeptidase and trypsin. The digests were separated using hydrophilic interaction chromatography and glycopeptides were collected. Aliquots of glycopeptides were purified by H2 18 The N-glycans were removed by hydrolysis with peptide-N-glycanase in O, and the glycosylated Asn residues were 18 N-glycosylated Asn residues were identified by labeling with O (IGOT method). Another aliquot of glycopeptide was heated in 0.1% v / v trifluoroacetic acid to remove sialic acid. Deglycosylated or desialylated glycopeptides were analyzed using a Tribrid mass spectrometer coupled to nanoflow liquid chromatography. Deglycosylated peptides were identified using the Mascot search engine to generate a list of CD31 glycosylated peptides. Deacylated glycopeptides were analyzed for glycan composition and structure using the Glyco-RIDGE method.

[0061] [Preparation and use of CD31 microarrays tagged with ABO blood group carbohydrate antigens (CD31-ABO microarrays)] CD31-ABO microarrays were prepared as follows: First, rCD31 (H-CD31, A-CD31, and B-CD31) bearing ABO blood group carbohydrate antigens was dissolved in a spotting solution (Matsunami Glass) to a concentration of 0.1 mg / mL, and spotted in triplicate onto an epoxysilane-coated slide glass (Schott) using a non-contact microarray printing robot (Microsys4000, Genomic Solutions). The slides were incubated overnight at 25°C for fixation, washed with probing buffer (Tris-buffered saline (pH 7.5) containing 25 mM Tris-HCl, 140 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 mM MnCl2, and 1 v / v% Triton X-100), and incubated with blocking reagent N102 (NOF Co.) at 20°C for 1 h. Finally, the slides were washed with TBS containing 0.02 w / v% NaN3, and stored at 4°C until use.

[0062] Human plasma (80 μL / well) was diluted 100-fold with probing buffer and incubated with CD31-ABO microarrays overnight at 20°C. After washing twice with 100 μL / well of probing buffer, 1 μg / mL of Cy3-conjugated goat anti-human Fc antibody (Jackson ImmunoResearch, 109-165-098) or Cy3-conjugated goat anti-human IgM antibody (Jackson ImmunoResearch, 109-165-043) was added and incubated for 1 h at 20°C. Fluorescent images were acquired using an evanescent field activated fluorescent scanner Bio-REX Scan200 (Rexxam). The fluorescent signal of each spot was quantified using Array Pro Analyzer version 4.5 (Media Cybernetics), and background values ​​were subtracted. Background values ​​were acquired from areas without immobilized samples (see Figure 1B). Anti-A and anti-B antibody levels (relative intensity) were calculated by subtracting the H-CD31 reaction from the A-CD31 or B-CD31 reaction of each sample.

[0063] [Statistical analysis] Continuous variables were expressed as mean ± standard deviation, and categorical variables were expressed as N and percentage. Mann-Whitney U test or Student's t test were used to compare two groups for continuous variables, and chi-square test was used to compare categorical data. The diagnostic potential of CD31-ABO microarray was determined by calculating plotted receiver operating characteristic (ROC) curves to evaluate its sensitivity and specificity for predicting acute ABMR after ABO blood type incompatible kidney transplantation. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were used to investigate its accuracy as a diagnostic tool for ABMR after ABO blood type incompatible kidney transplantation.

[0064] [Example 1] 1. Patient characteristics The proportion of males, age, and causes of end-stage renal disease were not significantly different between patients undergoing hemodialysis or ABO-incompatible kidney transplantation. However, the duration of hemodialysis was shorter in patients undergoing ABO-incompatible kidney transplantation than in patients undergoing hemodialysis. Table 1 below shows the characteristics of the two groups of patients divided by the presence of ABMR after ABO-incompatible kidney transplantation. In Table 1, the abbreviations mean the following:

[0065] HLA: human leukocyte antigen WIT:worm ischemic time TIT:total ischemic time FK: tacrolimus CyA: cyclosporine A MMF: mycophenolate mofetil AZ: azathioprine CPA: Cyclophosphamide POD: post-operative days N / A:not applicable

[0066] In addition, in Table 1, * indicates the average number of HLA mismatches for each transplant patient. ** indicates the number of patients who underwent antibody depletion before kidney transplantation. *** indicates antibody titer measured by the isohemagglutinin method.

[0067] [Table 1]

[0068] There were no significant differences between the two groups, except for antibody ablation therapy before ABO-incompatible kidney transplantation. Antibody titers against donor blood types measured using the isohemagglutinin method before desensitization therapy and on the day of ABO-incompatible kidney transplantation were not significantly different between the two groups. The median date of diagnosis of postoperative ABMR was 5 days (range: 0-19 days).

[0069] 2.ABO glycan analysis of rCD31 and human kidney CD31 by MS Using the Glyco-RIDGE method, the MS spectrum signals of two core glycopeptides (VLENSTK (SEQ ID NO: 4) containing Asn-453 and EGKPFYQMTSNATQAFWTK (SEQ ID NO: 5) containing Asn-551) derived from rCD31 protein purified from the medium of HEK193H, HEK293A, and HEK293B cells were compared, and the predicted glycan compositions were assigned. Characteristic peaks of glycopeptides with glycan compositions corresponding to H-, A-, and B-type glycans were observed in the MS spectra. CD31 proteins prepared from human kidney tissues of patients with blood group antigens O, A, and B were also analyzed. Several target glycopeptides derived from one of the two core peptides (VLENSTK (SEQ ID NO: 4) including Asn-453) were commonly found in rCD31 and human kidney tissue-derived CD31 proteins bearing blood group antigens O, A, and B, and the MS / MS spectra obtained from the target glycopeptides were compared and extensively analyzed. All MS / MS spectra of glycopeptides showed fucosylation with N-acetylglucosamine linked to Asn. Furthermore, the presence of glycan-derived signals indicating glycan compositions corresponding to blood groups H, A, and B was suggested. Taken together, MS analysis of all glycopeptides generated from rCD31 or human kidney tissue-derived CD31 proteins bearing blood group antigen types O, A, and B strongly suggested the presence of the corresponding blood group glycan structures.

[0070] 3. CD31-ABO microarray antibody levels The results of antibody levels measured using CD31-ABO microarrays are shown in Tables 2 and 3.

[0071] [Table 2]

[0072] [Table 3]

[0073] CD31-ABO microarray specifically detected anti-A and anti-B antibodies. Anti-A and anti-B antibody levels were not significantly different between volunteers and hemodialysis populations. Anti-A IgG and anti-B IgG antibody levels were significantly higher in the O population than in the B and A populations, respectively (p<0.01). However, anti-A IgM and anti-B IgM antibody levels were not significantly different between the O and B, and between the O and A populations, respectively.

[0074] 4. Prediction of ABMR after ABO-incompatible kidney transplantation using anti-A and anti-B antibodies FIG. 2 shows the results of a receiver operating characteristic (ROC) curve analysis for prediction of antibody-mediated rejection (ABMR) based on early anti-A and anti-B antibody levels measured by CD31-ABO microarray. As shown in Figure 2, the areas under the receiver operating characteristic curves (AUCs) suggested that, except for anti-B IgG antibodies, antibody levels measured by CD31-ABO microarray before desensitization therapy could significantly predict acute ABMR occurring after ABO blood type-incompatible kidney transplantation. Table 4 shows a comparison of the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of CD31-ABO microarray results in predicting ABMR after ABO blood type-incompatible kidney transplantation.

[0075] [Table 4]

[0076] As shown in Table 4, it was suggested that the CD31-ABO microarray method could predict ABMR more significantly than the isohemagglutinin method. Specifically, the CD31-ABO microarray method had high sensitivity, specificity, PPV, and NPV for both anti-A and anti-B antibodies when the IgG antibody level or IgM antibody level before desensitization therapy for the donor blood type was 30,000 or more. More specifically, when the anti-A IgG antibody level or anti-A IgM antibody level was 30,000 or more, the sensitivity for predicting ABMR after type A incompatible kidney transplantation was 83.3%, the specificity was 94.1%, the PPV was 90.9%, and the NPV was 88.9%. When the anti-B IgG antibody level or anti-B IgM antibody level was 30,000 or more, the sensitivity for predicting ABMR after type B incompatible kidney transplantation was 60.0%, the specificity was 100%, the PPV was 100%, and the NPV was 81.8%.

[0077] 5. Comparison of titers using isohemagglutinin assay and antibody levels using CD31-ABO microarray assay Anti-A and anti-B antibodies in all plasma samples were measured using both the RBC isohemagglutinin method and the CD31-ABO microarray method, and the results are shown in Figure 3 (anti-IgG antibody results) and Figure 4 (anti-IgM antibody results).

[0078] As shown in Figures 3 and 4, the antibody titers measured by the isohemagglutinin assay and the antibody levels measured by the CD31-ABO microarray assay were roughly correlated between the volunteer and hemodialysis groups. However, the antibody levels measured by the CD31-ABO microarray assay differed between samples with the same antibody titers measured by the isohemagglutinin assay.

[0079] Next, to examine whether the antibody levels measured by the CD31-ABO microarray method could predict acute ABMR after ABO-incompatible kidney transplantation more accurately than the antibody titers measured by the conventional isohemagglutinin method, we compared the early anti-A and anti-B antibody levels in samples taken before desensitization therapy. The results are shown in Figure 5 (anti-A antibody) and Figure 6 (anti-B antibody).

[0080] As shown in Figure 5 and Table 1 above, in patients with type A incompatible kidney transplants, the anti-A IgG antibody titers measured by the isohemagglutinin method in samples taken before desensitization therapy tended to be higher in the ABMR(+) group than in the ABMR(-) group (median: 128 vs. 32, p = 0.180), but the difference was not significant. In contrast, the anti-A IgG antibody levels measured by the CD31-ABO microarray method were significantly higher in the ABMR(+) group than in the ABMR(-) group (median: 54721 vs. 10211, p < 0.001). As shown in Figure 5a, 10 of 12 patients (83.3%) with ABMR had anti-A IgG antibody levels of >30,000 on CD31-ABO microarray in samples taken before desensitization therapy. In contrast, only 1 of 17 patients (5.9%) without ABMR had an anti-A IgG antibody level of >30,000.

[0081] As shown in Table 1 above, there was no significant difference in the anti-A IgM antibody titers measured by the isohemagglutinin method in samples taken before desensitization therapy between the ABMR(-) and ABMR(+) groups (median: 32 vs. 16, p=0.324). In contrast, the anti-A IgM antibody levels measured by the CD31-ABO microarray method were significantly higher in the ABMR(+) group than in the ABMR(-) group (median: 14277.5 vs. 58887, p=0.03). As shown in Figure 5b, in the ABMR(-) group, no patient had an anti-A IgM antibody level of more than 30,000. In contrast, 4 of 12 patients with ABMR had anti-A IgM antibody levels of more than 30,000 in the CD31-ABO microarray assay of samples taken before desensitization therapy. 8 of 12 patients with ABMR had anti-A IgM antibody levels of less than 30,000 in the CD31-ABO microarray assay of samples taken before desensitization therapy. However, all 6 of these 8 patients had anti-A IgG antibody levels of more than 30,000 in the CD31-ABO microarray assay (see the square samples in the graph in Figure 5b). It was probably inferred that 6 of the 8 patients with anti-A IgM antibody levels less than 30,000 induced ABMR by anti-A IgG antibodies. In conclusion, 10 of 12 ABMR patients (83.3%) were type A incompatible kidney transplant recipients with initial anti-A IgG antibody or anti-A IgM antibody levels exceeding 30,000, as shown by the results of CD31-ABO microarray analysis.

[0082] As shown in Figure 6 and Table 1 above, there was no significant difference in the anti-B IgG antibody titers and anti-B IgM antibody titers using the isohemagglutinin method in samples taken before desensitization therapy between the ABMR(-) and ABMR(+) groups. In contrast, the anti-B IgG antibody levels using the CD31-ABO microarray method were not significantly different, but were higher in the ABMR(+) group than in the ABMR(-) group (median: 16,378 vs. 1,970, p = 0.208). The anti-B IgM antibody levels using the CD31-ABO microarray method were significantly higher in the ABMR(+) group than in the ABMR(-) group (median: 14,480 vs. 3,480, p = 0.047). As shown in Figure 6, in the ABMR(-) group, no patient had anti-B IgG antibody levels and anti-B IgM antibody levels exceeding 30,000. In contrast, three out of five patients (60.0%) with ABMR had initial anti-B IgG antibody levels and anti-B IgM antibody levels exceeding 30,000 by CD31-ABO microarray analysis in samples taken before desensitization therapy.

[0083] Samples obtained after ABO-incompatible kidney transplantation were also examined in the same manner. The results are shown in Figure 7 (anti-A antibodies) and Figure 8 (anti-B antibodies). The timing of plasma sample collection varied in each case. For patients without ABMR, plasma samples collected within one month after ABO-incompatible kidney transplantation were used. For patients with ABMR, plasma samples collected before treatment when ABMR was clinically suspected were used.

[0084] As shown in FIG. 7, in five patients after type A incompatible kidney transplantation, the anti-A IgG antibody level or anti-A IgM antibody level exceeded 30,000 by CD31-ABO microarray method. As shown in FIG. 8, in one patient after type B incompatible kidney transplantation, the anti-B IgG antibody level was more than 30,000 by CD31-ABO microarray method. However, no significant differences were observed between the ABMR(-) and ABMR(+) groups in anti-A and anti-B antibody levels measured by both the isohemagglutinin method and the CD31-ABO microarray method.

[0085] [Consideration] In this study, we developed a method to evaluate anti-A / anti-B antibodies that react with ABO blood group antigens expressed on renal vascular endothelial cells. CD31-ABO microarrays were prepared using rCD31 proteins with ABO glycans added. By comparing the rCD31 used in the CD31-ABO microarray with CD31 derived from human renal tissue by MS analysis, it was confirmed that the ABH glycans used in the CD31-ABO microarray mimicked the ABO blood group antigens on human renal vascular endothelial cells.

[0086] In addition, the anti-A / anti-B antibody titers were roughly correlated between the isohemagglutinin method and the CD31-ABO microarray method. However, there was a large variability in the anti-A / anti-B antibody levels by the CD31-ABO microarray method among patients who showed the same antibody titers using the isohemagglutinin method. The content of the desensitization therapy was not significantly different between the two groups of patients with and without ABMR. Furthermore, there was no significant difference in the antibody titers by the isohemagglutinin method on the day of ABO blood type incompatible kidney transplantation (see Table 1 above). Despite no significant difference in the antibody titers by the isohemagglutinin method between the two groups, both the anti-A IgG antibody levels and the anti-A IgM antibody levels by the CD31-ABO microarray method were significantly higher in patients with acute ABMR after A blood type incompatible kidney transplantation. The sensitivity, specificity, PPV, and NPV of predicting acute ABMR in type A-incompatible kidney transplants were highest when the cutoff value of the antibody level using CD31-ABO microarray was >30,000. In type B-incompatible kidney transplants, the sensitivity of predicting acute ABMR when the cutoff value of the antibody level was >30,000 was not as high as that in type A-incompatible kidney transplants. However, in type B-incompatible kidney transplant patients, ABMR did not occur when the anti-B antibody level using CD31-ABO microarray did not exceed 30,000 (specificity of predicting ABMR was 100%).

[0087] In addition, antibody levels measured by CD31-ABO microarray were low in samples taken when acute ABMR was clinically suspected. This suggests that anti-A and anti-B antibodies react with ABO antigens on vascular endothelial cells of the transplanted kidney and are adsorbed after ABO-incompatible kidney transplantation. Because the adsorption of anti-A and anti-B antibodies is specific to renal vascular endothelial cells, it may have a greater effect on plasma antibody levels measured by CD31-ABO microarray than by isohemagglutinin method. Therefore, CD31-ABO microarray may not be suitable for use after ABO-incompatible kidney transplantation.

[0088] To evaluate the usefulness of the CD31-ABO microarray method for predicting ABMR in ABO blood type incompatible kidney transplants, further evaluation using a larger number of samples is necessary (particularly, the number of samples obtained from patients with type B incompatible kidney transplants in this study was small). In addition, plasma samples on the day of ABO blood type incompatible kidney transplantation were not stored and could not be examined in this study. Since it is important to know the antibody levels that should be reduced by desensitization therapy before ABO blood type incompatible kidney transplantation in terms of suppressing the onset of ABMR, a future challenge will be to analyze the antibody levels on the day of kidney transplantation using the CD31-ABO microarray method.

[0089] These results demonstrate that the risk of acute ABMR after ABO blood type incompatible kidney transplantation can be accurately determined before ABO blood type incompatible kidney transplantation by using a CD31-ABO microarray that mimics the ABO blood type antigens on renal vascular endothelial cells. [Industrial Applicability]

[0090] According to the method of this embodiment, the onset of antibody-mediated reactions after ABO blood type incompatible kidney transplantation can be accurately predicted before ABO blood type incompatible kidney transplantation, allowing ABO blood type incompatible kidney transplantation to be performed more safely.

Claims

1. 1. A method for testing the possibility of antibody-mediated rejection in an animal undergoing an ABO blood type incompatible kidney transplant, comprising: a contacting step of contacting the body fluid sample derived from the subject animal with three types of glycoproteins consisting of CD31 protein to which any one of ABO blood group antigens has been added; a detection step of detecting anti-A antibodies and anti-B antibodies bound to the CD31 protein having A antigen bound thereto and the CD31 protein having B antigen bound thereto, among the glycoproteins contained in the body fluid sample; Including, In the detection step, the possibility of antibody-mediated rejection in the test animal is tested by comparing with a criterion that when the binding amount of the anti-A antibody or the anti-B antibody to the CD31 protein attached with the A antigen or the CD31 protein attached with the B antigen exceeds a predetermined criterion, an antibody-mediated rejection reaction is highly likely to occur, and when the binding amount is equal to or less than a predetermined criterion, an antibody-mediated rejection reaction is unlikely to occur; The method, wherein the three types of glycoproteins are immobilized on a solid support, and the solid support is a microplate.

2. The method of claim 1 , wherein the bodily fluid sample is blood, serum, or plasma.

3. The method described in claim 1 or 2, wherein the subject animal has not yet undergone an ABO blood type incompatible kidney transplant.

Citation Information

Patent Citations

  • Blood group antigen fusion polypeptide and method of use thereof

    JP2009131279A

  • Methods and systems for detecting and characterizing ABO antibodies

    JP2014525570A

  • Sugar chain array substrate and method for detection of sugar chain-binding molecule using the same

    WO2009057755A1